Abstract:Background and Objective The pharmacokinetics of lurasidone have been studied in healthy Japanese and Caucasian subjects, but not in Chinese subjects. The objective of this study was to evaluate the pharmacokinetics, safety, and tolerability of oral lurasidone in healthy Chinese subjects. Methods This single-center, randomized, parallel-group, placebo-controlled, and double-blind study evaluated the pharmacokinetics, safety, and tolerability of oral lurasidone administered as a single dose (20, 40, and 80 mg) and multiple doses for 5 days (40 mg administered once daily) in healthy Chinese subjects. Serum lurasidone and its metabolites were quantified using high-performance liquid chromatography–mass spectrometry. Pharmacokinetic parameters for lurasidone and its metabolites were calculated using non-compartmental analysis of WinNonlin ® version 6.2. Safety analyses were recorded using physical examinations, vital signs, electrocardiogram, and clinical laboratory tests. Results Serum concentrations of lurasidone reached maximum concentration ( C max ) within 1.0–3.0 h after each single dose, and then decreased biphasically, with a mean half-life ( t ½ ) from 18.1 to 25.5 h over the dose range of 20–80 mg. The area under the concentration–time curve (AUC) and C max values increased approximately dose proportionally. Lurasidone steady state was achieved after 5 days of daily dosing and the accumulation index of the AUC during a dosage interval (AUC τ ) was 1.25, smaller than theoretical cumulative coefficient (1.76). Similar results were observed for the metabolites (ID-14283, ID-14326, and ID-11614). No severe adverse events (AEs) were observed in the single- or multiple-dose studies and no subject discontinued from the study due to AEs. The most common reported AEs were somnolence, increased blood prolactin, and restlessness, with a higher rate as dose increased. Conclusion Lurasidone was safe and well-tolerated in healthy Chinese subjects, following single doses in the range of 20 to 80 mg and multiple doses of 40 mg/day for 5 days. Linear increase in lurasidone C max and AUC values were seen following single doses from 20 to 80 mg. There was no unexpected accumulation after multiple administrations of lurasidone at 40 mg/day, and the pharmacokinetic characteristics were consistent with the conclusion obtained in the previous studies. Trial Registration: Clinicaltrials.gov identifiers NCT02174510 and NCT02174523.

The pharmacokinetics of lamivudine in healthy Chinese subjects: Short report

Correlation of the Occurrence of YMDD Mutations with HBV Genotypes, HBV-DNA Levels, and HBeAg Status in Chinese Patients with Chronic Hepatitis B During Lamivudine Treatment

Population Pharmacokinetics and Model-Informed Precision Dosing of Lamivudine in Chinese HIV-infected Patients with Mild and Moderate Impaired Renal Function.

Pharmacokinetics and Safety of Pitavastatin Calcium Tablets in Chinese Healthy Volunteers after a Single Oral Dose Administration

P414 ASSESSMENT OF THE CHANGE IN ESTIMATED GLOMERULAR FILTRATION RATES IN TELBIVUDINE- OR LAMIVUDINE-BASED TRERAPY IN PATIENTS WITH CHRONIC HEPATITIS B

Measuring Adherence Using Lamivudine Concentration Monitoring in Young Children

Pharmacokinetics of Tenofovir Disoproxil Fumarate Tablets in Healthy Volunteers from Western China

Pharmacokinetic and Bioequivalence Evaluation of Single-Tablet and Separate-Tablet Regimens for Ainuovirine, Lamivudine, and Tenofovir Disoproxil Fumarate in Chinese Healthy Subjects

Pharmacokinetics of peramivir after single intravenous doses in healthy Chinese subjects.

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men

Randomized, Three-Arm Study To Optimize Lamivudine Efficacy In Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients

Pharmacodynamic Effects and Kinetic Disposition of Rabeprazole in Relation to CYP2C19 Genotype in Healthy Chinese Subjects1

Management of hepatitis B in China.

[Pharmacokinetics and Relative Bioavailability of Ziprasidone Tablets in Chinese Healthy Volunteers].

A One-Year Trial of Lamivudine for Chronic Hepatitis B

Single- and Multiple-Dose Pharmacokinetics, Safety and Tolerability of Lurasidone in Healthy Chinese Subjects

Clinical pharmacokinetics of gemifloxacin following single oral dose administration in healthy Chinese male subjects

Telbivudine Versus Lamivudine in Chinese Patients with Chronic Hepatitis B: Results at 1 Year of A Randomized, Double-Blind Trial

Study of Pharmacokinetics of Vardenafil Tablets in Chinese Male Healthy Volunteers

Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients

The Current Status of Lamivudine-Treated Patients with Chronic Hepatitis B